Your Name (required)
Your Email (required)
We strive to develop innovative products for the safe, effective treatment of rare diseases and unmet needs for our number one priority- Our patients.
Our technology platform includes a unique, GMP compliant,
validated process that has proven capable of producing industrial quantities
of pure recombinant human proteins.
We have established partnerships for the most important markets,
the United States of America, and Europe, and also have our own
commercialisation activities in the Netherlands, Austria and Germany.
Click to download the Pharming Annual Report 2016
ROTH – PHARM: 4Q16 Recap - Momentum Building into 2017 Biotech company Pharming Group NV announces the analyst report completed by [...]
9mar - 10All DayFull year results 2016
9 (Thursday) - 10 (Friday)
23marAll DayAnnual Report 2016
All Day (Thursday)
17may07:00- 09:001st Quarterly Results
(Wednesday) 07:00 - 09:00
24may14:00- 17:00Annual General Meeting 2017
(Wednesday) 14:00 - 17:00